<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nervus intermedius neuralgia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nervus intermedius neuralgia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nervus intermedius neuralgia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ivan Garza, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nervus intermedius neuralgia is a rare condition characterized by brief paroxysms of pain felt deeply in the auditory canal. Other terms previously used for this condition include geniculate neuralgia and Hunt neuralgia.</p><p>This topic will review the clinical features, diagnosis, and treatment of nervus intermedius neuralgia. Other causes of focal head and facial pain are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">"Overview of craniofacial pain"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Nervus intermedius neuralgia is a painful condition caused by neuropathic dysfunction restricted to structures innervated by the nervus intermedius. Neuralgia is a form of neuropathic pain that is characterized by paroxysmal, brief (seconds to a few minutes), shock-like or lightning-like pain that follows a peripheral or cranial nerve distribution and can spread to adjacent areas in the course of the attack [<a href="#rid1">1-3</a>].</p><p class="headingAnchor" id="H2277358036"><span class="h2">Anatomy</span><span class="headingEndMark"> — </span>The nervus intermedius (also called the intermediate nerve of Wrisberg or glossopalatine nerve) is a small branch of the facial nerve (cranial nerve VII) that carries general visceral efferent, special visceral afferent (taste), and general somatic afferent fibers  (<a class="graphic graphic_figure graphicRef68923" href="/z/d/graphic/68923.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>]. Nerve fibers from the superior salivary and solitary nuclei in the pons merge to become the nervus intermedius in the subarachnoid space. These fibers then join nerve fibers from the facial nucleus. The cell bodies of the nervus intermedius dwell in the geniculate ganglion. Peripheral axons carry parasympathetic information to the lacrimal and nasopalatine glands, and sensory information is transmitted from portions of the pinna and middle ear, the mastoid process, the eustachian tube, and parts of the tongue [<a href="#rid4">4-6</a>].</p><p class="headingAnchor" id="H2528363055"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Although the pain and other clinical features localize to structures supplied by the nervus intermedius, there have not been studies to prove that the neuralgic pain originates in the geniculate ganglion or along the nervus intermedius [<a href="#rid5">5</a>].</p><p>Some investigators believe that compression of the nerve by an adjacent blood vessel is an important mechanism [<a href="#rid7">7,8</a>], and relief of pain by vascular decompression of the intermediate nerve provides some support for this hypothesis [<a href="#rid7">7</a>]. However, the role of vascular compression in the pathogenesis of nervus intermedius neuralgia and other neuralgias remains uncertain because otalgia can arise from other cranial nerve afferents in the ear [<a href="#rid9">9,10</a>]. In some surgical reports, section or decompression of a combination of cranial nerves V, VII, VIII, IX, X, and/or XI has been necessary to obtain relief [<a href="#rid1">1,4</a>].</p><p>Nervus intermedius neuralgia may also occur in the setting of inflammation at the geniculate ganglion due to herpes zoster infection [<a href="#rid11">11,12</a>]. Neuralgic pain can occur both from inflammation related to the acute infection or from secondary neuronal damage due to fibrosis with membrane hyperexcitability following an infection.</p><p class="headingAnchor" id="H4"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Nervus intermedius neuralgia is rare, and only limited data from case series and reports are available regarding the incidence, prevalence, and risk factors associated with this condition. In a 2021 review of published reports that included 127 patients with nervus intermedius neuralgia, approximately 66 percent were female [<a href="#rid13">13</a>]. In a systematic review published in 2013, females accounted for 14 of 15 (93 percent) surgical cases of nervus intermedius neuralgia [<a href="#rid14">14</a>].</p><p>The median age of symptom onset is 41 to 45 years old, but symptoms have also been reported in young children as well as adults up 89 years old [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H4139278003"><span class="h2">Ear pain</span><span class="headingEndMark"> — </span>Nervus intermedius neuralgia consists of unilateral, severe paroxysmal pain felt within the depths of the ear. Symptoms are typically brief, lasting seconds or a few minutes, and may occur as single paroxysms or as a rapid volley. However, some patients may report constant baseline pain [<a href="#rid13">13</a>]. The pain can be sharp or burning. Symptoms typically involve the auricle but can also radiate from the auditory canal to the parieto-occipital region or to trigeminal sensory zones on the face [<a href="#rid11">11,13,14</a>]. A variable refractory period follows attacks; the duration of the refractory period shortens as the disease progresses.</p><p class="headingAnchor" id="H2279596399"><span class="h2">Triggers</span><span class="headingEndMark"> — </span>Attacks can be provoked by nonpainful stimulation (allodynia) of trigger points or zones in the posterior wall of the ear canal  (<a class="graphic graphic_figure graphicRef139110" href="/z/d/graphic/139110.html" rel="external">figure 2</a>). Pain may also occur spontaneously [<a href="#rid13">13</a>]. The presence of an attack trigger (ie, auditory canal stimulation) was once considered a characteristic feature of nervus intermedius neuralgia. However, a systematic review found that a trigger was described in only 3 of 10 patients with available data [<a href="#rid14">14</a>]. In a review of 48 cases of nervus intermedius neuralgia, the most common triggers were [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Touch to the ear or external auditory canal – 23 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Air movement or cold temperature – 21 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Jaw movement (eg, eating, talking) – 19 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Noise – 10 percent</p><p class="bulletIndent1"><span class="glyph">●</span>No trigger – 35 percent</p><p></p><p class="headingAnchor" id="H2620486607"><span class="h2">Other neurologic symptoms</span><span class="headingEndMark"> — </span>Altered taste perception, such as a sense of bitter taste, can occur in some individuals, as can disorders of lacrimation or salivation [<a href="#rid1">1,5,11</a>]. Dizziness and vertigo occur in up to approximately 25 percent of patients [<a href="#rid13">13</a>]. Involvement of parasympathetic fibers of the nervus intermedius or other anastomosing cranial nerves may account for these other neurologic symptoms  (<a class="graphic graphic_figure graphicRef68923" href="/z/d/graphic/68923.html" rel="external">figure 1</a>). (See <a class="local">'Anatomy'</a> above.)</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Nervus intermedius neuralgia should be considered in patients with transient episodes of isolated ear pain. The diagnosis of nervus intermedius neuralgia is made in patients with characteristic ear pain after excluding other neurologic and otolaryngologic causes [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4004215224"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnosis of nervus intermedius neuralgia, according to the International Classification of Headache Disorders, 3<sup>rd</sup> edition (ICHD-3), requires fulfilling all of the following criteria [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Paroxysmal attacks of unilateral pain in the distribution of nervus intermedius</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain has all of the following characteristics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lasting from a few seconds to minutes</p><p class="bulletIndent2"><span class="glyph">•</span>Severe in intensity</p><p class="bulletIndent2"><span class="glyph">•</span>Shooting, stabbing, or sharp in quality</p><p class="bulletIndent2"><span class="glyph">•</span>Precipitated by stimulation of a trigger area in the posterior wall of the auditory canal and/or periauricular region</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>Although the ICHD-3 diagnostic criteria mandate the presence of a trigger area to produce brief pain in the auditory canal, a trigger is not always present, and, for some patients, the pain may occasionally be constant [<a href="#rid13">13,15</a>]. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H7"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis for nervus intermedius neuralgia includes other conditions that cause otalgia. These conditions may be broadly divided into otologic and neuralgic (referred) causes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Otologic conditions</strong> – Conditions that cause swelling or injury to the ear may present with ear pain, similar to nervus intermedius neuralgia. These include local infections (eg, otitis media or otitis externa), trauma, and neoplasm [<a href="#rid15">15</a>]. Otologic conditions may be identified by findings on physical examination, otoscopic evaluation, or imaging. (See  <a class="medical medical_review" href="/z/d/html/6872.html" rel="external">"Acute otitis media in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6866.html" rel="external">"External otitis: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6544.html" rel="external">"Evaluation and management of middle ear trauma"</a> and  <a class="medical medical_review" href="/z/d/html/5231.html" rel="external">"Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuralgic conditions</strong> – Nerves that can cause pain at the ear include branches of cranial nerves V, VII, IX, and X, and upper cervical nerve roots (C2 through C3) via the great auricular and lesser occipital nerves  (<a class="graphic graphic_figure graphicRef139110" href="/z/d/graphic/139110.html" rel="external">figure 2</a>) [<a href="#rid15">15</a>]. Pathology affecting any of these neural structures can potentially refer pain to the ear. Such conditions include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glossopharyngeal neuralgia</strong> – Glossopharyngeal neuralgia is the main disorder in the differential diagnosis of nervus intermedius neuralgia due to adjacent areas of cutaneous innervation. Glossopharyngeal neuralgia typically presents with brief episodes of triggered pain in the ear that also involves the throat, base of the tongue, and angle of the jaw. However, some patients who fulfill diagnostic criteria for nervus intermedius neuralgia [<a href="#rid11">11</a>] may have a variant of glossopharyngeal neuralgia with pain paroxysms initially restricted to the ear [<a href="#rid14">14</a>]. In such cases, the discriminating pharyngeal pain of glossopharyngeal neuralgia may not occur until years later [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">"Overview of craniofacial pain", section on 'Glossopharyngeal neuralgia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ramsay Hunt syndrome</strong> – The classic triad of symptoms in Ramsay Hunt syndrome (herpes zoster oticus) is unilateral ear pain, ipsilateral facial paralysis, and vesicles in the auditory canal or auricle. Some patients also develop tinnitus, vertigo, or other cranial nerve symptoms due to spread of inflammation to nearby ganglia and cranial nerves. (See  <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Ramsay Hunt syndrome (herpes zoster oticus)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Trigeminal neuralgia</strong> – Trigeminal neuralgia can present with brief paroxysms of facial pain, including the ear, that may be triggered by external stimuli, similar to nervus intermedius neuralgia. However, the distribution of pain in trigeminal neuralgia typically involves broader areas of the face, corresponding to one or more major branches of the trigeminal nerve [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">"Trigeminal neuralgia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Occipital neuralgia</strong> – Occipital neuralgia pain may present with ear pain due to involvement of the lateral aspect of the lesser occipital nerves but typically also includes occipital pain and tenderness, aching, or paresthesias at the nuchal ridge [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/3330.html" rel="external">"Occipital neuralgia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Central neuropathic facial pain</strong> – Cerebral and cervical spine conditions that cause dysfunction along somatosensory tracts may lead to pain-producing, hypersensitized pathways. Structural lesions from stroke or demyelinative lesions, such as from multiple sclerosis, can result in neuropathic pain, including at the auricle. C1 myelitis, for example, has been reported to give rise to neuralgic otalgia [<a href="#rid19">19</a>]. Pain may be constant or intermittent. Central neuropathic pain may be distinguished by the onset of symptoms after a cerebral or spinal insult that produces a sensory deficit; the pain subsequently develops in the area corresponding to chronic sensory deficit but may extend to adjacent areas. (See  <a class="medical medical_review" href="/z/d/html/3324.html" rel="external">"Central neuropathic facial pain"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Auricular neuralgias</strong> – Other rare cranial neuralgias that primarily affect the ear include great auricular neuralgia and auriculotemporal neuralgia. These may be idiopathic or due to secondary (structural) causes. The location of pain may be used to distinguish these conditions from nervus intermedius neuralgia  (<a class="graphic graphic_figure graphicRef139110" href="/z/d/graphic/139110.html" rel="external">figure 2</a>). Great auricular neuralgia causes pain at the ear, ipsilateral jaw, and neck, correlating with the sensory distribution of the great auricular nerve. The auriculotemporal nerve is a terminal nerve branch of the mandibular (V3) nerve that can cause pain in the tragus, parotid gland, and temporal region of the head. (See  <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">"Overview of craniofacial pain", section on 'Auricular neuralgias'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Red ear syndrome</strong> – Red ear syndrome is a rare condition characterized by transient, burning ear pain as well as redness. Symptoms may be restricted to the auricle or can involve the face as well. Symptoms may persist for several minutes, up to an hour. (See  <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">"Overview of craniofacial pain", section on 'Red ear syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The diagnosis of nervus intermedius neuralgia requires an evaluation to exclude other causes of symptoms. This includes a clinical examination to evaluate for otologic conditions as well as diagnostic imaging to exclude alternative causes and to identify any structural sources of pain such as vascular compression of the nerve.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical examination</strong> – A general clinical examination to evaluate for systemic infection should include a direct inspection of the auditory canal and tympanic membrane as well as referral to an otolaryngologist to evaluate for other otologic causes of ear pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic imaging</strong> – For patients with symptoms of nervus intermedius neuralgia, we recommend a contrast-enhanced magnetic resonance imaging (MRI) of the brain with dedicated brainstem sequences (such as the fast imaging employing steady-state acquisition [FIESTA] protocol) and a magnetic resonance angiogram (MRA) of the head to evaluate for vascular compression or other underlying structural conditions. Computed tomography (CT) and computed tomography angiography (CTA) of the head are alternative imaging options for patients unable to obtain MRI and MRA. Brain imaging is useful to identify entities such as stroke, demyelinating lesions, or a tumor at the cerebellopontine angle. MRA or CTA is useful show an ectatic blood vessel compressing the nervus intermedius. However, the sensitivity and specificity of imaging studies for identifying a secondary cause of ear pain is unknown for patients with suspected nervus intermedius neuralgia and a normal neurologic examination.</p><p></p><p class="bulletIndent1">Urgent imaging is warranted for patients with nervus intermedius neuralgia symptoms accompanied by neurologic deficits. Additional imaging may be performed when clinical features are atypical, such as patients with progressive symptoms or those with neurologic deficits, and initial brain MRI and MRA are nondiagnostic [<a href="#rid15">15</a>]. Options include MRI of the cervical spine, face, temporomandibular joint, or soft tissue of the neck or CT of the temporal bones.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other testing</strong> – Laboratory testing to assess for systemic infection or herpes zoster is reserved for patients with suggestive clinical features such as fever or vesicles in the auditory canal.</p><p></p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H10"><span class="h2">Pharmacotherapy</span><span class="headingEndMark"> — </span>Medications are first-line treatment and are effective for many patients with nervus intermedius neuralgia. The rarity of nervus intermedius neuralgia has precluded accumulation of high-quality data to guide therapy [<a href="#rid4">4,5</a>]. Pharmacologic treatment for nervus intermedius neuralgia is based largely on efficacy of treatments used for other cranial neuralgias, mainly trigeminal neuralgia. (See  <a class="medical medical_review" href="/z/d/html/5283.html" rel="external">"Trigeminal neuralgia", section on 'Medical treatment'</a>.)</p><p class="headingAnchor" id="H4031206378"><span class="h3">Initial treatment</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> extended release for the initial treatment of most patients with nervus intermedius neuralgia, based on efficacy for trigeminal neuralgia. Our typical starting dose of carbamazepine extended release is 100 mg twice daily. The daily dose can be increased by 200 mg up to every 2 to 3 days as tolerated and as needed for pain relief, typically up to 1200 mg daily in two divided doses.</p><p>Adverse effects of <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> include drowsiness, dizziness, nausea, and vomiting; slow titration may minimize these effects. Carbamazepine-induced leukopenia is a potential adverse effect but is usually benign. The Stevens-Johnson syndrome and toxic epidermal necrolysis are additional rare complications, particularly during the first eight weeks of therapy. They are significantly more common (estimated incidence of 5 percent) among patients with the <em>HLA-B*1502</em> allele. This allele occurs almost exclusively in patients of Asian ancestry, including South Asian Indians. Screening for this allele is recommended in patients with Asian ancestry prior to starting carbamazepine. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'</a> and  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis", section on 'HLA polymorphism and pharmacogenetics'</a>.)</p><p class="headingAnchor" id="H2535376379"><span class="h3">Alternative treatment options</span><span class="headingEndMark"> — </span>For patients who do not tolerate or respond to <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, we suggest either <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> or <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">baclofen</a> [<a href="#rid13">13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">Oxcarbazepine</a> is started at 150 mg twice daily. The daily dose can be increased if needed for pain relief by up to 300 mg each week as tolerated up to 1800 mg daily in divided doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">Baclofen</a> is started at 5 mg three times daily. The total daily dose can be increased as tolerated and needed for pain relief by 15 to 30 mg every three days, up to a daily dose of 80 mg daily in divided doses.</p><p></p><p>Other options that may provide benefit include <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, and tricyclic antidepressants (eg, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>) [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Surgery for refractory symptoms</span><span class="headingEndMark"> — </span>Neurosurgery is considered as a last resort when pharmacotherapy fails or when adverse effects of medications significantly reduce quality of life. However, there are limited data to guide operative techniques [<a href="#rid20">20</a>]. The opinion of an experienced neurosurgeon, familiar with the detailed anatomy of the nervus intermedius and its variants and with intraoperative anatomic findings, should be obtained to choose the most appropriate intervention [<a href="#rid20">20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excision</strong> – Surgical treatment for refractory nervus intermedius neuralgia frequently involves excision of the nervus intermedius and geniculate ganglion [<a href="#rid21">21</a>], with or without exploration and/or section of cranial nerves V, IX, and X [<a href="#rid22">22</a>]. Sectioning of the nervus intermedius alone is often ineffective [<a href="#rid23">23,24</a>]. One series of 64 patients who had excision of the nervus intermedius and geniculate ganglion reported "excellent" results in 63 patients, but outcomes were not objectively defined in this report [<a href="#rid21">21</a>]. Complications included a temporary partial facial paralysis in 11 patients (17 percent). In addition, permanent ipsilateral xerophthalmia is an expected outcome due to sectioning of the greater petrosal nerve as part of the surgical approach to the geniculate ganglion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microvascular decompression</strong> – Decompression of cranial nerves V, IX, and X, with or without section of the nervus intermedius, is another option [<a href="#rid6">6,25,26</a>]. In a series of 10 patients with nervus intermedius neuralgia treated with microvascular decompression who had long-term (&gt;12 months) follow-up, an "excellent" outcome was reported for three patients and partial relief for six [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H2242283464"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Limited data are available regarding the prognosis of nervus intermedius neuralgia. Chronic symptoms that persist for years have been reported in observational studies of patients undergoing surgical treatment for refractory nervus intermedius neuralgia [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H944108247"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115871.html" rel="external">"Society guideline links: Neuropathic pain"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Nervus intermedius neuralgia is a rare disorder characterized by pain felt deeply in the auditory canal. The median age of symptom onset is 41 to 45 years old, and females are predominantly affected. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The symptoms of nervus intermedius neuralgia consist of episodes of severe paroxysmal ear pain felt in the depths of the ear  (<a class="graphic graphic_figure graphicRef139110" href="/z/d/graphic/139110.html" rel="external">figure 2</a>). Symptoms are typically brief, lasting seconds or a few minutes. Pain may occur spontaneously or may be associated with a trigger zone in the posterior wall of the ear canal. Altered taste perception, such as a sense of bitter taste, can occur in some individuals, as can disorders of lacrimation or salivation. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of nervus intermedius neuralgia is made in patients with characteristic ear pain after excluding other neurologic and otolaryngologic causes. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Differential diagnosis</strong> – The differential diagnosis for nervus intermedius neuralgia includes other conditions that cause otalgia. Otologic causes include local infections (eg, otitis media or otitis externa), trauma, and neoplasm. Neuralgic causes include glossopharyngeal neuralgia, Ramsay Hunt syndrome, trigeminal neuralgia, occipital neuralgia, central neuropathic facial pain syndrome, auricular neuralgias, and red ear syndrome. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuroimaging</strong> – For patients with suspected nervus intermedius neuralgia, we recommend a contrast-enhanced brain MRI with dedicated brainstem sequences to rule out a structural lesion or vascular compression. Additional imaging, such as MRI of the cervical spine, face, temporomandibular joint, or soft tissue of the neck or CT of the temporal bones, are performed when clinical features are atypical and initial brain MRI and MRA are nondiagnostic. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – For patients with nervus intermedius neuralgia, we suggest initial treatment with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternatives include <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">baclofen</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, and <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">Neurosurgical treatment is reserved for patients with symptoms refractory to pharmacotherapy.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bruyn GW. Nervus intermedius neuralgia (Hunt). Cephalalgia 1984; 4:71.</a></li><li class="breakAll">Peter C, Watson N. Trigeminal neuropathy and neuralgia. In: Neurological therapeutics: Principles and practice, Noseworthy JH (Ed), Martin Dunitz, London, New York 2003. p.1849.</li><li class="breakAll">Goodwin JG, Bajwa ZH. Understanding the patient with chronic pain. In: Principles and practice of pain medicine, Bajwa ZH (Ed), McGraw-Hill, Warfield, CA 2004. p.55.</li><li class="breakAll">Nurmikko TJ, Jensen TS. Trigeminal neuralgia and other facial neuralgias. In: The headaches, Olesen J, Goadsby PJ, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.1053.</li><li class="breakAll">Boes CJ, Copobianco DJ, Cutrer FM, et al. Headache and other craniofacial pain. In: Neurology in clinical practice, Bradley WG, Daroff RB, Fenichel GM, et al (Eds), Butterworth Heinemann, Philadelphia 2004. p.2055.</li><li><a class="nounderline abstract_t">Tubbs RS, Steck DT, Mortazavi MM, Cohen-Gadol AA. The nervus intermedius: a review of its anatomy, function, pathology, and role in neurosurgery. World Neurosurg 2013; 79:763.</a></li><li><a class="nounderline abstract_t">Sakas DE, Panourias IG, Stranjalis G, et al. Paroxysmal otalgia due to compression of the intermediate nerve: a distinct syndrome of neurovascular conflict confirmed by neuroimaging. Case report. J Neurosurg 2007; 107:1228.</a></li><li><a class="nounderline abstract_t">Yeh HS, Tew JM Jr. Tic convulsif, the combination of geniculate neuralgia and hemifacial spasm relieved by vascular decompression. Neurology 1984; 34:682.</a></li><li><a class="nounderline abstract_t">Shah RK, Blevins NH. Otalgia. Otolaryngol Clin North Am 2003; 36:1137.</a></li><li><a class="nounderline abstract_t">Monstad P. Microvascular decompression as a treatment for cranial nerve hyperactive dysfunction--a critical view. Acta Neurol Scand Suppl 2007; 187:30.</a></li><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Tsau PW, Liao MF, Hsu JL, et al. Clinical Presentations and Outcome Studies of Cranial Nerve Involvement in Herpes Zoster Infection: A Retrospective Single-Center Analysis. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Robblee J. A pain in the ear: Two case reports of nervus intermedius neuralgia and narrative review. Headache 2021; 61:414.</a></li><li><a class="nounderline abstract_t">Smith JH, Robertson CE, Garza I, Cutrer FM. Triggerless neuralgic otalgia: a case series and systematic literature review. Cephalalgia 2013; 33:914.</a></li><li><a class="nounderline abstract_t">DeLange JM, Garza I, Robertson CE. Clinical reasoning: a 50-year-old woman with deep stabbing ear pain. Neurology 2014; 83:e152.</a></li><li><a class="nounderline abstract_t">O'Neill F, Nurmikko T, Sommer C. Other facial neuralgias. Cephalalgia 2017; 37:658.</a></li><li><a class="nounderline abstract_t">Ansari H, Robertson CE, Lane JI, et al. Auriculotemporal neuralgia secondary to TMJ synovial cyst: a rare presentation of a rare entity. Headache 2013; 53:1662.</a></li><li><a class="nounderline abstract_t">Duvall JR, Garza I, Kissoon NR, Robertson CE. Great Auricular Neuralgia: Case Series. Headache 2020; 60:247.</a></li><li><a class="nounderline abstract_t">Martinez-Thompson JM, Garza I, Cutrer FM, Robertson CE. C1 Myelitis Presenting With Neuralgic Otalgia. Headache 2017; 57:126.</a></li><li><a class="nounderline abstract_t">Clifton WE, Grewal S, Lundy L, et al. Clinical implications of nervus intermedius variants in patients with geniculate neuralgia: Let anatomy be the guide. Clin Anat 2020; 33:1056.</a></li><li><a class="nounderline abstract_t">Pulec JL. Geniculate neuralgia: long-term results of surgical treatment. Ear Nose Throat J 2002; 81:30.</a></li><li><a class="nounderline abstract_t">Rupa V, Saunders RL, Weider DJ. Geniculate neuralgia: the surgical management of primary otalgia. J Neurosurg 1991; 75:505.</a></li><li><a class="nounderline abstract_t">Teton ZE, Holste KG, Hardaway FA, et al. Pain-free survival after vagoglossopharyngeal complex sectioning with or without microvascular decompression in glossopharyngeal neuralgia. J Neurosurg 2019; 132:232.</a></li><li><a class="nounderline abstract_t">Holste KG, Hardaway FA, Raslan AM, Burchiel KJ. Pain-free and pain-controlled survival after sectioning the nervus intermedius in nervus intermedius neuralgia: a single-institution review. J Neurosurg 2018; 131:352.</a></li><li><a class="nounderline abstract_t">Inoue T, Shima A, Hirai H, et al. Nervus Intermedius Neuralgia Treated with Microvascular Decompression: A Case Report and Review of the Literature. NMC Case Rep J 2017; 4:75.</a></li><li><a class="nounderline abstract_t">Onoda K, Kawaguchi A, Takaya Y, et al. A Case of Nervus Intermedius Neuralgia. World Neurosurg 2020; 137:89.</a></li><li><a class="nounderline abstract_t">Lovely TJ, Jannetta PJ. Surgical management of geniculate neuralgia. Am J Otol 1997; 18:512.</a></li><li><a class="nounderline abstract_t">Peris-Celda M, Oushy S, Perry A, et al. Nervus intermedius and the surgical management of geniculate neuralgia. J Neurosurg 2018; 131:343.</a></li></ol></div><div id="topicVersionRevision">Topic 3331 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6370459" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nervus intermedius neuralgia (Hunt).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6370459" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nervus intermedius neuralgia (Hunt).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6370459" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nervus intermedius neuralgia (Hunt).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6370459" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nervus intermedius neuralgia (Hunt).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6370459" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nervus intermedius neuralgia (Hunt).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22484073" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The nervus intermedius: a review of its anatomy, function, pathology, and role in neurosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077963" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Paroxysmal otalgia due to compression of the intermediate nerve: a distinct syndrome of neurovascular conflict confirmed by neuroimaging. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6538661" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tic convulsif, the combination of geniculate neuralgia and hemifacial spasm relieved by vascular decompression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15025013" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Otalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17419825" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Microvascular decompression as a treatment for cranial nerve hyperactive dysfunction--a critical view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32235469" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical Presentations and Outcome Studies of Cranial Nerve Involvement in Herpes Zoster Infection: A Retrospective Single-Center Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33586784" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A pain in the ear: Two case reports of nervus intermedius neuralgia and narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23444079" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Triggerless neuralgic otalgia: a case series and systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25313382" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical reasoning: a 50-year-old woman with deep stabbing ear pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28133989" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Other facial neuralgias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24020967" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Auriculotemporal neuralgia secondary to TMJ synovial cyst: a rare presentation of a rare entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31749202" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Great Auricular Neuralgia: Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861805" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : C1 Myelitis Presenting With Neuralgic Otalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31837174" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical implications of nervus intermedius variants in patients with geniculate neuralgia: Let anatomy be the guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11816385" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Geniculate neuralgia: long-term results of surgical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1885967" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Geniculate neuralgia: the surgical management of primary otalgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30641844" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pain-free survival after vagoglossopharyngeal complex sectioning with or without microvascular decompression in glossopharyngeal neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30117769" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pain-free and pain-controlled survival after sectioning the nervus intermedius in nervus intermedius neuralgia: a single-institution review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28840083" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nervus Intermedius Neuralgia Treated with Microvascular Decompression: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953093" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A Case of Nervus Intermedius Neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9233495" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Surgical management of geniculate neuralgia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30095334" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nervus intermedius and the surgical management of geniculate neuralgia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
